White Papers / Tech Papers

What FDA CRLs Reveal About E&L

Extractables and Leachables (E&L) issues are quietly derailing nearly one in five drug applications.

Company Logo

Released By Solvias

Extractables and Leachables (E&L) issues are quietly derailing nearly one in five drug applications, as shown by hundreds of recent FDA Complete Response Letters. This white paper reveals the most common mistakes behind these setbacks—and offers practical, expert-backed strategies to build stronger E&L programs that protect timelines and speed products to market.

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters